The common chemotherapy regimen for hepatocellular carcinoma is usually 2-3 days. Depending on the patient’s reaction level to chemotherapy, adjuvant symptom-reducing drugs may be given, depending on the patient’s different conditions. If the patient’s reaction to chemotherapy drugs is not particularly strong, the drugs are basically infused in 2-3 days. If the response is strong, adjuvant symptom-reducing drugs may be administered subsequently. From the pathological type, mainly hepatocellular carcinoma, which accounts for more than 90% of the primary tumor, surgery is still recommended in the early and middle stages, and chemotherapy is not needed after surgery, but most patients have already reached locally advanced stage when they are diagnosed and have lost the chance of surgery. In case of systemic metastasis, systemic chemotherapy should be given. Tumor cells are naturally resistant to chemotherapy drugs, and the overall effect of chemotherapy is not particularly satisfactory, but with the application of oxaliplatin or tegeo, gemcitabine and other high-efficiency and low-toxicity drugs in recent years, especially the oxaliplatin-based mFOLFOX4 regimen, certain effects have been achieved in hepatocellular carcinoma with satisfactory results.